Japan · Delayed Price · Currency is JPY EnBio Holdings Statistics
Total Valuation
EnBio Holdings has a market cap or net worth of JPY 6.49 billion. The enterprise value is 13.19 billion.
| Market Cap | 6.49B |
| Enterprise Value | 13.19B |
Important Dates
The last earnings date was Friday, May 15, 2026.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
EnBio Holdings has 8.12 million shares outstanding. The number of shares has increased by 0.08% in one year.
| Current Share Class | 8.12M |
| Shares Outstanding | 8.12M |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 18.97% |
| Owned by Institutions (%) | 8.75% |
| Float | 3.74M |
Valuation Ratios
The trailing PE ratio is 24.47.
| PE Ratio | 24.47 |
| Forward PE | n/a |
| PS Ratio | 0.51 |
| PB Ratio | 0.70 |
| P/TBV Ratio | 0.74 |
| P/FCF Ratio | 54.57 |
| P/OCF Ratio | 5.56 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.10, with an EV/FCF ratio of 110.83.
| EV / Earnings | 49.77 |
| EV / Sales | 1.04 |
| EV / EBITDA | 6.10 |
| EV / EBIT | 8.15 |
| EV / FCF | 110.83 |
Financial Position
The company has a current ratio of 2.20, with a Debt / Equity ratio of 1.14.
| Current Ratio | 2.20 |
| Quick Ratio | 1.22 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | 4.93 |
| Debt / FCF | 89.52 |
| Interest Coverage | 9.04 |
Financial Efficiency
Return on equity (ROE) is 2.72% and return on invested capital (ROIC) is 2.84%.
| Return on Equity (ROE) | 2.72% |
| Return on Assets (ROA) | 4.59% |
| Return on Invested Capital (ROIC) | 2.84% |
| Return on Capital Employed (ROCE) | 9.16% |
| Weighted Average Cost of Capital (WACC) | 3.11% |
| Revenue Per Employee | 125.05M |
| Profits Per Employee | 2.62M |
| Employee Count | 101 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 2.42 |
Taxes
In the past 12 months, EnBio Holdings has paid 663.00 million in taxes.
| Income Tax | 663.00M |
| Effective Tax Rate | 72.46% |
Stock Price Statistics
The stock price has increased by +36.99% in the last 52 weeks. The beta is 0.58, so EnBio Holdings's price volatility has been lower than the market average.
| Beta (5Y) | 0.58 |
| 52-Week Price Change | +36.99% |
| 50-Day Moving Average | 814.14 |
| 200-Day Moving Average | 670.64 |
| Relative Strength Index (RSI) | 46.49 |
| Average Volume (20 Days) | 116,370 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EnBio Holdings had revenue of JPY 12.63 billion and earned 265.00 million in profits. Earnings per share was 32.69.
| Revenue | 12.63B |
| Gross Profit | 3.69B |
| Operating Income | 1.62B |
| Pretax Income | 915.00M |
| Net Income | 265.00M |
| EBITDA | 2.16B |
| EBIT | 1.62B |
| Earnings Per Share (EPS) | 32.69 |
Balance Sheet
The company has 4.04 billion in cash and 10.65 billion in debt, with a net cash position of -6.62 billion or -815.14 per share.
| Cash & Cash Equivalents | 4.04B |
| Total Debt | 10.65B |
| Net Cash | -6.62B |
| Net Cash Per Share | -815.14 |
| Equity (Book Value) | 9.33B |
| Book Value Per Share | 1,139.16 |
| Working Capital | 6.23B |
Cash Flow
In the last 12 months, operating cash flow was 1.17 billion and capital expenditures -1.05 billion, giving a free cash flow of 119.00 million.
| Operating Cash Flow | 1.17B |
| Capital Expenditures | -1.05B |
| Depreciation & Amortization | 543.00M |
| Net Borrowing | 557.00M |
| Free Cash Flow | 119.00M |
| FCF Per Share | 14.66 |
Margins
Gross margin is 29.20%, with operating and profit margins of 12.82% and 2.10%.
| Gross Margin | 29.20% |
| Operating Margin | 12.82% |
| Pretax Margin | 7.24% |
| Profit Margin | 2.10% |
| EBITDA Margin | 17.12% |
| EBIT Margin | 12.82% |
| FCF Margin | 0.94% |
Dividends & Yields
This stock pays an annual dividend of 9.00, which amounts to a dividend yield of 1.14%.
| Dividend Per Share | 9.00 |
| Dividend Yield | 1.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 27.17% |
| Buyback Yield | -0.08% |
| Shareholder Yield | 1.03% |
| Earnings Yield | 4.08% |
| FCF Yield | 1.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
EnBio Holdings has an Altman Z-Score of 1.6 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.6 |
| Piotroski F-Score | 7 |